Nektar Therapeutics (NKTR +0.8%
) is a beneficiary of the FDA's approval
of Affymax's (AFFY +35.4%
) peginesatide treatment of anemia in dialysis patients. Nektar has an exclusive agreement
under which it will provide Affymax with its proprietary technology for use in the drug's manufacture in exchange for manufacturing revenue, milestone and other payments.